Affordable Access

Publisher Website

An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.

Authors
  • Sams, Lara1
  • Slagle, Ashley F2
  • Symonds, Tara1
  • Antonova, Jenya3
  • Globe, Denise4
  • 1 Clinical Outcomes Solutions, Folkestone, Kent, England, UK.
  • 2 Aspen Consulting, LLC, Steamboat Springs, CO, USA.
  • 3 Compass Strategy and Research Inc., San Francisco, CA, USA.
  • 4 Gilead Sciences, Foster City, CA, USA. Electronic address: [email protected].
Type
Published Article
Journal
Value in Health
Publisher
Elsevier
Publication Date
Dec 01, 2023
Volume
26
Issue
12
Pages
1675–1680
Identifiers
DOI: 10.1016/j.jval.2023.08.012
PMID: 37748736
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We aimed to ascertain the frequency and types of Food and Drug Administration (FDA)-identified clinical outcome assessment (COA) violations in US pharmaceutical promotional materials from 2013 to 2021 by updating the review by Symonds et al (covering the period 2006-2012 for patient-reported outcomes [PRO] measures), expanding to infringements across all types of COAs, and grouping by efficacy or overall patient experience. Warning letters (WLs) and untitled letters (ULs) issued by the FDA's Office of Prescription Drug Promotion were reviewed for COA violations and classified by their type: (1) COA measure not fit for purpose, (2) issue with study design or interpretation of results, and (3) inadequate statistical analysis. From 2013 to 2021, the FDA issued 22 WLs and 65 ULs. Year 2013 showed the highest number of letters issued (n = 24). Of the total 87 letters reviewed, 22 (25%) contained a COA violation, consisting of 6 WLs (27%) and 16 ULs (25%), including 20 (23%) with a PRO-related violation. The most common violations cited "study design or interpretation of results" (21 of 22 [95%]). Overall, the absolute number of WLs and ULs issued declined when comparing 2006 to 2012 with 2013 to 2021. Despite the overall reduction, this review still identified 25% of letters citing COA infringements (23% with PRO issues), which was similar to the prior review (19% PRO infringements). This may be due to increased FDA attention to patient-focused drug development. Copyright © 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times